Speed up your therapy decisions and alleviate patient anxiety1.

Test for MSI, KRAS, NRAS and BRAF in only 3 hours and immediately start the right therapy.

IdyllaTM CRC Leaflet(link is external)


  • oncologist_cropped.jpg
    kras_ivd_1920_x_1080_px.png

    In vitro diagnostic tests

    IdyllaTM KRAS and NRAS-BRAF Mutation Tests

    The IdyllaTM mCRC Test Portfolio provides fast & reliable information on tumor mutation status for KRAS, NRAS and BRAF reducing the clinical turnaround time significantly to 1-2 days.

    In an independent comparison study, the IdyllaTM KRAS Mutation Test outperformed several NGS technologies as well as other PCR-based technologies with regard to sensitivity, turn-around-time and ease of use.1

    The IdyllaTM mCRC Test Portfolio includes 2 different RAS mutation tests:

    IdyllaTM KRAS Mutation Test  IdyllaTM NRAS-BRAF Mutation Test

    Contact Us   Request Demo


  • IdyllaTM MSI Test

    The IdyllaTM MSI Test provides fast & accurate information on MSI status directly from 1 FFPE colorectal cancer sample.1, 2, 3, 4   , showing high concordance (>97%) and lower failure rates compared to standard methods.5

    The use of 7 novel, monomorphic biomarkers provides unbiased test results and eliminates the need for paired normal tissue samples leading to optimal sample stewardship, resource optimization in the lab and eventually improved patient management.

    IdyllaTM MSI Test

    Contact Us   Request Demo






  • msi_ce_ivd_1920_x_1080_px_v3.png

    Clinical information

    RAS

    Colorectal cancer (CRC) remains the third most frequent and the second leading cause of cancer-associated mortalities worldwide. Oncogenic mutations in the RAS gene have been identified in ~50% of CRC with activating KRAS mutations identified in 46% and NRAS mutations in 5% of CRC cases.1  RAS mutations are important drivers of tumor resistance against anti-EGFR therapies. Therefore testing of mutations in exons 2, 3 and 4 of KRAS and NRAS is a requirement prior to initiating treatment with anti-EGFR therapy.2

    BRAF

    BRAF mutations are present in 8-15% of CRC cases.3The presence of a BRAF V600E mutation shows to be a poor prognostic factor in patients with mCRC.4 BRAF V600E status can be assessed alongside RAS to guide therapeutic decision-making for patients with mCRC.5

    MSI

    MSI status is a key biomarker for Lynch syndrome screening and for immune checkpoint inhibition treatment stratification  and detection of microsatellite instability (MSI) is currently recommended by guidelines for all newly diagnosed CRC patients.